University of Cambridge, Genomics England Ltd., and Illumina Collaborate to Sequence 10,000 Whole Human Genomes for National Health Service Patients Project Will Lay Foundation for Genomic Medicine Initiative Will Sequence 10,000 Whole Genomes of People with Rare Genetic Diseases Business Wire CAMBRIDGE, England -- October 21, 2013 University of Cambridge, Genomics England Ltd., and Illumina, Inc. (NASDAQ:ILMN) today announced the start of a three-year project that will sequence 10,000 whole genomes of children and adults with rare genetic diseases. The project represents a pilot for Genomics England Ltd., which will provide 2,000 samples, and marks the beginning of the national endeavor to sequence 100,000 genomes in the UK National Health Service (NHS), announced recently by the Prime Minister, David Cameron. “This project will bring enormous improvements to the care of patients with rare genetic diseases. It will shorten the gap between the first signs of ill-health in a person and providing a conclusive diagnosis by using the power of modern DNA sequencing methods,” said Dr. John Bradley, Director of the NIHR Cambridge Biomedical Research Centre, a partnership between the University of Cambridge and Cambridge University Hospitals. Today, most patients with a rare genetic disease go through a diagnostic odyssey to find the cause. For many, the long search remains unsuccessful, which not only prevents the delivery of optimal care, but also may aggravate the condition. To improve patient care in the UK National Health Service (NHS), the University of Cambridge will work with the team led by Dr. David Bentley, Vice President and Chief Scientist for Illumina, to develop the workflow and processes to bring routine clinical whole genome sequencing to the bedside. Illumina will deliver whole genome sequence data for the project using market-leading technology invented in Cambridge. “In 1997 sequencing a person’s entire genome as part of healthcare was just an idea and it has always been my hope that one day it would turn into reality and benefit thousands of patients,” said Shankar Balasubramanian, Professor of Chemistry at Cambridge University and inventor of the sequencing by synthesis technique that is used by Illumina’s instruments to read the DNA code. “We are excited to be partnering in this ground-breaking project to discover the genes underlying rare genetic diseases, which may lead to offering new tests and pave the way for new opportunities for treatment,” said Professor Mark Caulfield, Genomics England's Chief Scientist. There are an estimated 7,000 rare diseases and about 3.5 million people in the UK will be affected by a rare disease at some point in their life. “I am confident that the pioneering medical research by doctors, nurses, and scientists across the UK will receive broad support from the rare diseases community,” said Alastair Kent from Rare Diseases UK. Sarah-Jane Marsh, Chief Executive at Birmingham Children’s Hospital, added, "More than 5 percent of babies are born with a genetic disease. At the moment, too many of the affected families are unable to access the best diagnostics and treatment available.” The Rare Diseases Genomes Project will help to address this gap, and make the NHS a world leader in rare disease care. The cumulative knowledge which will be gained from collecting this data will improve treatment for many patients in the NHS and across the world. About the University of Cambridge The University of Cambridge was established over 800 years ago and is made up of 31 colleges and more than a hundred departments. Cambridge is one of the top-ranking universities in the world. Its mission is to contribute to society through the pursuit of education, learning, and research at the highest international levels of excellence. At the heart of that mission are its core values of freedom of thought and expression and freedom from discrimination. The University of Cambridge (http://www.cam.ac.uk/) has been the birthplace and touchstone for many of the most significant scientific breakthroughs since science began. After Cambridge celebrated its eight hundredth anniversary year in 2009 its eyes are firmly on the future, and ensuring that the modern University continues to be a leading international centre for study and research. Find out more at www.cam.ac.uk. About Cambridge University Hospitals and the Cambridge Biomedical Research Centre Based within the most outstanding NHS and University partnerships in the country, the NIHR Biomedical Research Centres are leaders in scientific translation. They receive substantial levels of funding from the National Institute for Health Research (NIHR) to translate fundamental biomedical research into clinical research that benefits patients and they are early adopters of new insights in technologies, techniques, and treatments for improving health. The Cambridge Biomedical Research Centre (http://www.cambridge-brc.org.uk/) coordinates the NIHR BioResource. About Genomics England Ltd. Genomics England (www.genomicsengland.co.uk) was incorporated on 17 April 2013 as a company to take forward the Prime Minister’s 100,000 Genome Project. The Project will introduce high-tech DNA mapping for rare diseases patients and those with cancer or infectious diseases and link that new data to the patient’s medical records. This will give doctors a new advanced understanding of a patient’s genetic make-up, condition, and treatment needs, ensuring they have access to the right drugs and personalised care far quicker than ever before. Genomics England Limited is owned by the UK Department of Health. About Illumina Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare. About Birmingham Children’s Hospital Birmingham Children’s Hospital NHS Foundation Trust provides the widest range of children’s health services for young patients from Birmingham the West Midlands and beyond, with over 240,000 patient visits every year. The Trust is the lead site for the national NIHR paediatric rare disease programme, a nationally designated specialist centre for epilepsy surgery and a trauma centre for the West Midlands and a national transplant centre. The hospital is a centre of excellence for complex heart conditions, the treatment of burns, cancer, and liver and kidney disease, and is also home to one of the largest Child and Adolescent Mental Health Services in the UK. Forward-Looking Statements This release may contain forward-looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release. Contact: Illumina Contacts: Investors: Rebecca Chambers 858-255-5243 firstname.lastname@example.org or Media: Jennifer Temple 858-882-6822 email@example.com or University of Cambridge Contact: Media: University of Cambridge Genevieve Maul Deputy Head of Research Communications Office of External Affairs and Communications +44 (0) 1223 76 5542 +44 (0) 7774 01 7464 firstname.lastname@example.org
University of Cambridge, Genomics England Ltd., and Illumina Collaborate to Sequence 10,000 Whole Human Genomes for National
Press spacebar to pause and continue. Press esc to stop.